Pre-made Istiratumab benchmark antibody ( Bispecific Mixed mAb and scFv, anti-IGF1R;ERBB3/Erbb-3 therapeutic antibody, Anti-IGFR/CD221/IGFIR/JTK13;FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-c-erbB3/p180-ErbB3/p45-sErbB3/p85-sErbB3 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Istiratumab biosimilar, Bispecific Mixed mAb and scFv, Anti-IGF1R;ERBB3/Erbb-3 Antibody: Anti-IGFR/CD221/IGFIR/JTK13;FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-c-erbB3/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Istiratumab (MM-141) is an experimental monoclonal antibody for the treatment of cancer. It is a bispecific antibody targeting IGF-1R and ErbB3.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-282-1mg	1mg	Inquiry
GMP-Bios-ab-282-10mg	10mg	Inquiry
GMP-Bios-ab-282-100mg	100mg	Inquiry
GMP-Bios-ab-282-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Istiratumab biosimilar, Bispecific Mixed mAb and scFv, Anti-IGF1R;ERBB3/Erbb-3 Antibody: Anti-IGFR/CD221/IGFIR/JTK13;FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-c-erbB3/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody
INN Name	Istiratumab
Target	IGF1R;Erbb-3
Format	Bispecific Mixed mAb and scFv
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	IgG1;na
VD LC	Kappa;Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2017
Year Recommended	2018
Companies	Adimab;Merrimack Pharmaceuticals
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Ovarian cancer;Pancreatic cancer;Solid tumours
Development Tech	na